Status:

COMPLETED

A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma

Lead Sponsor:

Montefiore Medical Center

Conditions:

Uterine Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE2

Brief Summary

Combination chemo/radiotherapy trials in advanced/recurrent endometrial cancer are ongoing. The optimal radiation modality, chemotherapeutic agents, and sequence of these regimens for the treatment of...

Detailed Description

Uterine papillary serous carcinoma (UPSC) is an uncommon, but aggressive variant of endometrial carcinoma that has a high recurrence rate and poor response to therapy. It has a propensity to metastasi...

Eligibility Criteria

Inclusion

  • Histologically documented uterine papillary serous carcinoma (UPSC) with no visible residual disease.
  • Surgical staging to include total abdominal hysterectomy, bilateral salpingo-oophorectomy, peritoneal washings, and lymph node samplings.
  • Age \> 18 years.
  • ECOG performance status of \< 2.
  • Written voluntary informed consent.

Exclusion

  • Patient has impairment of hepatic, renal or hematologic function as defined by the following baseline laboratory values:
  • Serum SGOT and /or SGPT \> 2.5 times the institutional upper limit of normal
  • Total serum bilirubin \> 1.5 mg/dl
  • History of chronic or active hepatitis
  • Serum creatinine \> 2.0 mg/dl
  • Platelets \< 100,000/mm3
  • Absolute neutrophil count (ANC) \< 1500/mm3
  • Hemoglobin \< 8.0 g/dl (the patient may be transfused prior to study entry)
  • Patient has severe or uncontrolled concurrent medical disease (eg. uncontrolled diabetes, unstable angina, myocardial infarction within 6 months, congestive heart failure, etc.)
  • Patient has been treated with myelosuppressive chemotherapy within three weeks prior to study entry.
  • Patient with any prior chemotherapy or radiotherapy for pelvic malignancy.
  • Patients with dementia or altered mental status that would prohibit the giving and understanding of informed consent at the time of study entry.

Key Trial Info

Start Date :

December 1 2001

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2011

Estimated Enrollment :

81 Patients enrolled

Trial Details

Trial ID

NCT00231868

Start Date

December 1 2001

End Date

July 1 2011

Last Update

August 12 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Montefiore Medical Center

The Bronx, New York, United States, 10461